Macula is the oval yellowish area surrounding the focal point of the retina in the eye. Macular edema is the state when liquid and protein begin collecting under the macula leading to swelling in the eye. Focal vision of the eye gets mutilated because of this swelling. The retina is the light-delicate tissue at the back of the eye and the macula is the piece of the retina in charge of sharp, straight-ahead vision. Diabetic retinopathy is the main reason for macular edema which happens because of diabetes. Macular edema can likewise be analyzed in quiet after eye surgery for waterfall, glaucoma, or retinal illness. Ailments which harm the vein in the retina can cause macular edema. Wavy or foggy vision to observable vision misfortune are essential side effects of macular edema. On the off chance that one eye influenced, there is half likelihood that other eye can likewise be influenced. Treatment for macular edema depends on why it is caused, and may take several months to resolve. During this time, it is important to follow the treatment regimen thoroughly.

On the basis of type, the macular edema market is divided into two types: cystoids macular edema (CME) and diabetic macular edema (DME). On the basis of treatment, the market is divided into drug therapy and laser treatment. The drug therapy segment is growing at a faster rate than the laser treatment segment as many ophthalmologists prefer drug therapy as the first line therapy to cure the disease. Moreover, laser treatment is costly as compared to drug therapy. On the basis of tests, the macular edema treatment market is segmented into visual acuity test; dilated exam test; and tonometry test. The adjustment in way of life have the expanded rate of diabetic patients is significant driving variables of macular therapeutics advertise comprehensively. Several eye disorders are caused due to changing climatic conditions. Growing aging population has led to increased occurrence of eye infections. Disappointment of eye surgery waterfall, glaucoma, or retinal ailment can likewise rise the market of macular edema therapeutics around the world. Limited number of approved drugs and high cost involved in laser treatment hinders the growth of the market.

Geographically, North America and Europe are mature markets for diabetic macular edema because a large proportion of the population suffers from diabetes. Lucentis and Ozurdex drugs have major market share in the therapeutics market. The market in Asia Pacific is also growing at a fast pace and India is set to play a major role as in 2015 (according to International Diabetes Federation) around 69.1 million cases of diabetes was reported in India and half of them affected with visual impairments. The Middle East & Africa market for macular edema is driven by the developing predominance of vision impedance. Advancement in the field of medicine is a key factor driving the development of the market. Expanding geriatric population around the district along with an expansion in the discretionary cash flow of the general population are the other driving components.

Some of the major companies operating in the macular edema market are Novartis, Roche, Allergan, Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, and Bausch & Lomb Incorporated.

 

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market 

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

.